ALBANY, NY – JUNE 9, 2023 – Late last night, the New York State Assembly passed Assembly Bill 1673a to increase access to biomarker testing, which can help determine the best treatment plan for each patient.
ALBANY, NY – JUNE 5, 2023 – This afternoon, the New York State Senate passed legislation that would ensure biomarker testing is covered by more insurance plans, including Medicaid, when patients need it.
AUSTIN, TX – MAY 30, 2023 – Yesterday, Texas Governor Greg Abbott signed Senate Bill 989 into law, making Texas the 11th state to expand access to biomarker testing. New York is considering comparable legislation through Assembly Bill 1673 / Senate Bill 1196.
ALBANY, NY – MAY 19, 2023 – Every year on May 20, patients and providers celebrate the invaluable work of clinical trials in the effort to eradicate all suffering and death from cancer.
ALBANY, NY – MAY 17, 2023 – Earlier today, oncologists and cancer survivors from across New York gathered at the Capitol to answer lawmakers’ questions about biomarker testing and ask for their support of Senate Bill 1196 / Assembly Bill 1673. This legislation, which is being sponsored by Asm.
ALBANY, NY – MAY 15, 2023 – Oncologists and cancer survivors from across New York will gather at the Capitol building on Wednesday, May 17 to answer lawmakers’ questions about biomarker testing and ask for their support of Senate Bill 1196 / Assembly Bill 1673, which aim to improve New Yorkers’ a
ALBANY, NY – MAY 1, 2023 – Earlier today New York State leaders released details on the agreed upon 2023-24 budget and will soon adopt each of the budget bills—the contents of which are a mixed bag at best in the fight against cancer.
ALBANY, NY –APRIL 21, 2023 – Cancer survivors, their families and caregivers from across New York will gather at the Capitol building on Tuesday, April 25 to ask legislators to support Senate Bill 1196 / Assembly Bill 1673, which aims to improve New Yorkers’ access to biomarker testing – a tool t
ALBANY, NY – APRIL 12, 2023 – Earlier today, JUUL announced it will pay $462 million to settle a multi-state investigation into its underage marketing practices to attract young consumers to its addictive e-cigarettes.